Tilsotolimod - Idera Pharmaceuticals

Drug Profile

Tilsotolimod - Idera Pharmaceuticals

Alternative Names: IMO-2125

Latest Information Update: 06 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idera Pharmaceuticals
  • Class Antineoplastics; Antivirals; Oligodeoxyribonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase I Solid tumours
  • Preclinical Colorectal cancer; Lymphoma; Pancreatic cancer
  • Discontinued Hepatitis C

Most Recent Events

  • 24 Jul 2018 Idera Pharmaceuticals plans a phase II trial for Melanoma in Netherlands (NTR7355)
  • 04 Jun 2018 Safety and efficacy data from phase I/II ILLUMINATE-204 in Malignant melanoma released by Idera Pharmaceuticals
  • 09 May 2018 Updated efficacy data from a phase I/II trial in Malingnant melanoma released by Idera Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top